Novartis’ experimental cholesterol drug, pelacarsen, has failed to reduce cardiovascular events in a critical trial, casting doubt on a multibillion-dollar market for Lp(a)-lowering therapies. This setback impacts rival drugs from Amgen and Eli Lilly, weakening the case for targeting this harmful cholesterol but not disproving it entirely. Investors now await further data to understand the implications for the broader class of potential Lp(a) treatments.
Novartis' experimental cholesterol drug, pelacarsen, has suffered a significant setback, failing to demonstrate a reduction in cardiovascular events in a crucial late-stage clinical trial. This development casts a cloud of uncertainty over a multibillion-dollar race to develop treatments for a particularly harmful form of cholesterol, Lp(a), impacting rival drugs in development by pharmaceutical giants Amgen and Eli Lilly.
Despite successfully lowering the levels of the detrimental Lp(a) cholesterol, the pelacarsen trial did not meet its primary endpoint of reducing cardiovascular events. This marks the first major clinical trial failure in the pursuit of targeted Lp(a) therapies, a market with significant unmet needs as currently, no approved treatments specifically target this risk factor. Approximately one in five people worldwide are estimated to be affected by elevated Lp(a) levels, which significantly increase the risk of cardiovascular diseases.
The failure of pelacarsen, co-developed with Ionis Pharmaceuticals, has sent ripples through the industry. Analysts suggest that while the hypothesis of targeting Lp(a) is weakened, it is not entirely disproven. The exact reasons for the trial's miss – whether related to the drug's mechanism, trial design, or the broader challenge of demonstrating benefit in a well-managed patient population – remain to be fully elucidated.
Full results from the trial are expected to be presented at an upcoming medical congress. Novartis stated that the findings would provide valuable insights into the relationship between Lp(a) lowering and cardiovascular outcomes, potentially guiding future strategies in cardiovascular risk management. Meanwhile, shares of Novartis experienced a 3% dip following the announcement, while Amgen saw a nearly 5% drop in extended trading, and Ionis Pharmaceuticals plummeted 10%.
Analysts had projected peak annual sales between $4 billion and $5 billion for pelacarsen, which would have been a significant revenue stream for Novartis, especially as it navigates a substantial patent cliff. The setback places increased pressure on Amgen's olpasiran and Eli Lilly's lepodisiran, the next experimental therapies in this class. While both utilize different mechanisms, the outcome of the pelacarsen trial raises the stakes considerably.
Citi analysts noted that the failure lowers confidence across the entire class of Lp(a)-lowering drugs, emphasizing the need for subsequent studies to demonstrate a clinically meaningful reduction in major adverse cardiovascular events. The market had anticipated a moderate benefit from pelacarsen, and its failure to meet even a modest threshold for statistical significance has been a key takeaway.
New Amsterdam Pharma, also developing an Lp(a)-lowering treatment, saw its U.S.-listed shares fall 12% in extended trading. Despite the setback, some analysts believe that alternative approaches used by other drugmakers could still lead to success, particularly for patients with extremely high Lp(a) levels.
Novartis Failure Raises Stakes for Amgen and Eli Lilly
The failure of Novartis' pelacarsen in a key cardiovascular trial has heightened the pressure on competitors like Amgen and Eli Lilly, who are also vying for a piece of the potentially lucrative market for Lp(a)-lowering drugs. Analysts had previously forecast substantial revenues for these therapies, with some modeling peak sales as high as $4 billion to $5 billion for pelacarsen alone.
The outcome of the pelacarsen trial introduces significant risk for other Lp(a)-driven cardiovascular disease studies. While Amgen's olpasiran and Eli Lilly's lepodisiran employ different technologies, the success of these drugs may now depend on demonstrating deeper reductions in Lp(a) or a more pronounced cardiovascular benefit to overcome the concerns raised by Novartis' failure.
Can Other Lp(a) Drugs Still Succeed?
The path forward for other Lp(a) drug developers remains uncertain but not entirely blocked. Different molecular mechanisms employed by competitors like Amgen and Eli Lilly could potentially achieve greater Lp(a) reduction or offer benefits in specific patient populations. However, the overall sentiment in the market has shifted, with investors now facing increased risk and demanding clearer evidence of efficacy and clinical benefit from remaining candidates in this high-stakes race.
